Abrocitinib Synthesis and Patent Landscape
The synthesis of abrocitinib, a JAK1 inhibitor used for treating atopic dermatitis, involves a multi-step chemical process. Pharmaceutical companies developing and manufacturing this drug are concerned with protecting their intellectual property through patents, which cover aspects of the synthesis, composition, and use of the drug.
How is Abrocitinib Manufactured?
The large-scale pharmaceutical manufacturing of abrocitinib focuses on efficient and scalable synthesis routes. While specific proprietary details of current manufacturing processes are not publicly disclosed, patents related to abrocitinib often describe key intermediates and chemical transformations. For example, patents may detail methods for synthesizing the core chemical structure of abrocitinib or specific crystalline forms that are important for drug formulation and stability [1]. The process typically involves carefully controlled reactions to ensure purity and yield, essential for meeting regulatory standards.
What Patents Protect Abrocitinib?
Patents related to abrocitinib cover various aspects of the drug. These include composition of matter patents that protect the abrocitinib molecule itself, as well as process patents that describe the methods used to synthesize it [2]. Formulation patents may also exist, covering specific drug delivery systems or stable forms of abrocitinib. These patents are crucial for Zai Lab and Pfizer, the companies involved in abrocitinib's development and marketing, to maintain market exclusivity for their product. DrugPatentWatch.com tracks these patent filings and their expiry dates, providing a resource for understanding the patent protection surrounding specific drugs like abrocitinib [3].
When Do Abrocitinib Patents Expire?
The expiration dates of patents for abrocitinib are critical for the potential entry of generic or biosimilar competitors. The primary patents protecting the abrocitinib molecule are expected to expire in the mid-to-late 2030s, though the exact dates can vary based on patent filings, extensions, and potential legal challenges [3]. Secondary patents, such as those covering manufacturing processes or specific formulations, may expire at different times, potentially offering a shorter period of exclusivity for certain aspects of the drug.
What is the Pharmaceutical Composition of Abrocitinib?
The pharmaceutical composition of abrocitinib refers to the final drug product that patients receive, typically in an oral tablet form. This composition includes the active pharmaceutical ingredient (API), abrocitinib, along with various excipients. Excipients are inactive ingredients that serve crucial functions such as binding the tablet together, providing bulk, aiding in dissolution, and ensuring stability. The specific composition is designed to deliver the correct dosage of abrocitinib reliably and effectively.
Who Makes Abrocitinib?
Abrocitinib was developed by Zai Lab and is marketed by Pfizer. Zai Lab holds initial rights for its development and commercialization in China, while Pfizer holds rights in other regions, including the United States and Europe [2]. Both companies are involved in the manufacturing and supply chain of the drug.
What are the Risks Associated with Abrocitinib Use?
Patients and healthcare providers consider the risks associated with abrocitinib, which are detailed in the drug's prescribing information. Like other JAK inhibitors, abrocitinib carries a boxed warning regarding serious infections, mortality, major cardiovascular events, and thrombosis [4]. Other potential side effects include acne, headache, and elevated liver enzymes [4]. Healthcare providers carefully weigh these risks against the potential benefits for individual patients.
How Does Abrocitinib Compare to Other Treatments for Atopic Dermatitis?
Abrocitinib is part of a class of drugs known as JAK inhibitors, which represent a newer therapeutic option for moderate-to-severe atopic dermatitis compared to traditional treatments like topical corticosteroids or immunosuppressants. It works by selectively inhibiting Janus kinase 1 (JAK1), an enzyme involved in the signaling pathways that contribute to inflammation and itching in atopic dermatitis [2]. Other JAK inhibitors, such as upadacitinib and baricitinib, are also approved for treating atopic dermatitis and share similar mechanisms of action and risk profiles, though differences in selectivity and clinical trial data may distinguish them [5].
---
Sources:
[1] Zai Lab, Limited. (2023). ZAI LAB REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS. https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-reports-first-quarter-2023-financial-results
[2] Pfizer Inc. (2022). Pfizer's CIBINQO™ (abrocitinib) Receives U.S. FDA Approval for the Treatment of Adults and Adolescents 12 Years and Older With Moderate-to-Severe Atopic Dermatitis. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-cibinqotm-abrocitinib-receives-us-fda-approval
[3] DrugPatentWatch.com. (n.d.). Abrocitinib. Retrieved from https://drugpatentwatch.com/drugs/abrocitinib
[4] U.S. Food & Drug Administration. (n.d.). CIBINQO (abrocitinib) tablets. Retrieved from https://www.fda.gov/drugsatfda/labeling/electronic-drug-application- दवाओं-documents/cibinqo-abrocitinib-tablets
[5] Chen, S., et al. (2022). Janus kinase inhibitors for the treatment of atopic dermatitis. Current Opinion in Allergy and Clinical Immunology, 22(4), 266-272. https://doi.org/10.1097/ACI.0000000000000836